October 02, 2023
Investors of biotherapeutics company Kiromic BioPharma Inc. asked a New York federal judge to initially approve a $2.3 million settlement in a suit accusing the company of touting prospects for two drug candidates ahead of a 2021 public offering despite knowing the U.S. Food and Drug Administration suspended the drugs' clinical trials.
August 08, 2022
An investor in biotherapeutics company Kiromic BioPharma Inc. has launched a proposed class action accusing the company and its leadership of touting prospects for two drug candidates ahead of a 2021 public offering despite the fact that the U.S. Food and Drug Administration had hit pause on clinical trials for both therapeutics.